Improving anemia management in patients on hemodialysis
Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients
This study is testing a new way to manage anemia in people on hemodialysis to see if it works better than the usual care they currently receive.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1296 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06463236 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to validate a management process for renal anemia specifically in patients undergoing maintenance hemodialysis. The study will compare the effectiveness of this structured approach against the current anemia management practices by primary care doctors. By utilizing a prospective randomized controlled trial design, the goal is to enhance the hemoglobin compliance rate among these patients and improve the understanding of anemia management guidelines among basic doctors. The trial seeks to establish a standardized protocol for managing renal anemia at the grassroots level.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been receiving regular hemodialysis for at least three months.
Not a fit: Patients who are planning to undergo kidney transplantation or have certain blood disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved anemia management and better health outcomes for patients on hemodialysis.
How similar studies have performed: Other studies have shown promise in improving anemia management in hemodialysis patients, suggesting that this approach could be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: ① Age over 18 years old; ② Receive regular hemodialysis at least twice a week for at least 3 months, and have no plans to stop hemodialysis within 6 months since the start of the trial; ③ The patient voluntarily participated in this study. Exclusion Criteria: * Patients who have planned to undergo kidney transplantation or terminate hemodialysis during the study period; ② Previous history of bone marrow hematopoietic system diseases, such as combined myelodysplastic syndrome, multiple myeloma, and other diseases; ③ Any known hereditary blood disease, such as thalassemia, sickle cell anemia, pure red blood cell aplasia, etc.; ④ Active or chronic gastrointestinal bleeding; ⑤ There was a severe infection within one week prior to screening.
Where this trial is running
Chengdu, Sichuan
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Daqing Hong
- Email: hongdaqing11@126.com
- Phone: 17716168101
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.